Mini Review - Journal of AIDS and HIV Treatment (2020) Volume 2, Issue 2
Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations
Jelani K. Grant1, Louis Vincent1, Bertrand Ebner1, Barry E. Hurwitz2,3,4, Maria L. Alcaide5, Claudia Martinez6*
1Department of Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, Florida, USA
2Behavioral Medicine Research Center, University of Miami, Miami, Florida, USA
3Department of Psychology, University of Miami, Coral Gables, Florida, USA
4Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, Florida, USA
5Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida,
6Department of Medicine, Division of Cardiovascular Disease, University of Miami Miller School of Medicine, Miami, Florida, USA
- *Corresponding Author:
- Claudia Martinez
Received date: August 08, 2020; Accepted date: October 07, 2020
Citation: Grant JK, Vincent L, Ebner B, Hurwitz BE, Alcaide ML, Martinez C. Early Insights into COVID-19 in Persons Living
with HIV and Cardiovascular Manifestations. J AIDS HIV Treat. 2020; 2(2): 68-74.
Copyright: © 2020 Grant JK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Persons living with HIV-1 (PLHIV) are at increased risk of cardiovascular complications in part due to the persistent inflammatory
state despite viral suppression. SARS-CoV-2, the virus causing COVID-19, was declared a pandemic virus in March 2020, and caused
over 30 million cases and 900,000 deaths worldwide to date. Individuals with COVID-19 are manifesting acute cardiovascular
complications because of the inflammatory response associated with SARS-CoV-2 infection. It is not yet known whether having
COVID-19 in the context of ongoing HIV-1 infection results in worse cardiovascular complications than in PLHIV who have not had
COVID-19 infection. In this review, the potential for exacerbated cardiovascular manifestations in persons coinfected with HIV-1 and
COVID-19 is considered.
At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China . The virus was designated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with coronavirus disease (COVID-19) as the disease caused by the virus . At the beginning of September 2020, globally there are more than thirty million confirmed COVID-19 cases , with a fatality rate ranging from 1.4% in mainland China to 7.2% in Italy . Advanced age, underlying co-morbidities and immunocompromised states serve as significant risk factors for severe infection with SARS-CoV-2 [4-8]. Patients with SARS-CoV-2 infection can manifest a variety of cardiovascular complications including myocardial dysfunction, acute coronary syndrome, thromboembolic complications including pulmonary embolism leading to right heart failure among others [9-11]. SARS-CoV-2
infection is caused by binding of the viral surface spike
protein to the human angiotensin-converting enzyme 2
(ACE2) receptor following activation of the spike protein
by transmembrane protease serine 2 (TMPRSS2) .
ACE2 is expressed in the lung (principally Type II alveolar
cells) and appears to be the predominant portal of entry
. ACE2 is highly expressed in the heart as well,
counteracting the effects of angiotensin II in states with
excessive activation of the renin-angiotensin system such as
hypertension (HTN), heart failure (HF) and atherosclerosis
. Therefore, patients with these conditions are thought
to be at higher risk for severe COVID-19 manifestations.
In addition, SARS-CoV-2 infection drives the progression
of systemic inflammation and immune cell overactivation,
which may lead to a ‘cytokine storm’ and elevated levels
of inflammatory cytokines, such as interleukin (IL)-6, IL-
7, IL-22, which have been associated with oxygen radical formation and cardiovascular injury . Indeed, autopsy
studies have noted detectable SARS-CoV-2 RNA (and, in
some cases, antigen) in the heart, in addition to respiratory
tract specimens [16,17].
At present, over 1.4 million persons in the US are living with the Human Immunodeficiency Virus-1 (HIV) infection . The southern US is disproportionally affected by HIV, accounting for greater than 15 cases per 100,000 persons [19-21]. The advent of anti-retroviral therapy (ART) has led to an increased life expectancy in PLHIV and recent estimates indicate that over 50% of PLHIV in the US are older than 55 years of age . Aging and the status of immune activation and inflammation associated with chronic HIV, results in an increase of non- HIV comorbidities such as HTN, diabetes mellitus (DM), coronary artery disease, hyperlipidemia, and metabolic syndrome [23-25]. In fact, epidemiological evidence indicates that cardiovascular disease (CVD) is the leading cause of death among PLHIV in the US [26-29]. Although evidence of the pathophysiological effects of COVID-19 has rapidly emerged, research pertaining to the natural history of COVID-19 pathophysiology in the context of HIV-1 spectrum disease is scant. The increased prevalence of CVD and immunocompromised state in PLHIV suggest that PLHIV may experience worsened disease progression if infected with SARS-CoV-2. In addition, studies suggesting beneficial effects of ART, and the use of antivirals such as Remdesivir underscore the importance of evaluating the potential interactions between COVID-19 and HIV- 1 infections and the risk of deleterious cardiovascular outcomes.
Cardiovascular Manifestations of COVID-19
The frequency of myocardial injury, as reflected by elevation in cardiac troponin levels, is variable among hospitalized patients with COVID-19, with reported frequencies of 7 to 28 percent [9,30,31]. Of 416 patients with COVID-19 who were hospitalized in Wuhan, China, 19.7% had high-sensitivity troponin I (hs-TnI), an index of myocardial injury, above the 99th percentile upper reference limit on admission. Cardiac injury, as indexed by hs-TnI levels, were associated with a higher mortality compared to those without cardiac injury (42 of 82 [51.2%] vs 15 of 334 [4.5%]; p<0.001) . Patients with elevated hs-TnI were older and had more comorbidities (including chronic heart failure in 14.6 versus 1.5 percent) and complications (acute respiratory distress syndrome, acute kidney injury, electrolyte disturbances, hypoproteinemia and coagulation abnormalities) compared with those without myocardial injury. The mechanisms underlying myocardial injury in these cases are not yet understood; however, in keeping with other severe respiratory illnesses, direct (“non-coronary”) myocardial damage may also play a role . Hypoxia and electrolyte abnormalities, both known to contribute to the development of acute
arrhythmias, have been frequently reported in the acute
phase of severe COVID-19 illness . However, the exact
contribution of COVID-19 infection to the development of
arrhythmias remains unknown . In a multinational
cohort of 8,910 patients from Asia, Europe, and North
America, 304 patients (3.4 percent) had a history of
arrhythmia, this prevalence was more than twice as
common in patients who died from COVID-19 (6.8 versus
3.2 percent among survivors) . Studies thus far on
COVID-19 hospitalizations, document the presence of
cardiac arrhythmias in 17 percent of the these entire
cohort of patients, but 44 percent of patients admitted
to an intensive care unit displayed arrhythmias . The
most common arrhythmia in patients with COVID-19
was sinus tachycardia followed by atrial fibrillation, atrial
flutter, and monomorphic and polymorphic ventricular
The incidence of CAD following COVID-19 infections has been between 4.2 and 25 percent in Chinese reports [8,34,36]. Type I myocardial infarctions, due to the potential inflammatory and cardiotoxic mechanisms mentioned above, have been postulated to occur from atherosclerotic plaque rupture . However, it appears that with COVID-19 infection, the majority of myocardial infarctions are type 2 and related to the primary infection, hemodynamic, and respiratory derangement . There have been reports of increased coronary artery thrombus burden in patients with ST elevation myocardial infarction (STEMI), which is consistent with an increased frequency during the pandemic of thrombotic strokes, particularly in young people . Alterations in the coagulation system, abnormal platelet function, or abnormal vascular endothelial function have also been postulated as possible mechanisms . Some COVID-19 case reports have described findings consistent with a diagnosis of “clinically suspected myocarditis” or possible stress cardiomyopathy [41-45]. However, COVID-19 is likely a potential new cause of viral myocarditis, with studies reporting interstitial mononuclear inflammatory infiltrates or cardiac cell necrosis not typical of ischemic injury [46,47]. However, pathological studies have demonstrated changes in multiple organs, not only in lungs and heart but also liver and kidney.
In the previous Severe Acute Respiratory Syndrome (SARS) outbreak, chloroquine (CQ) and hydroxychloroquine (HCQ) were reported to have anti- SARS-CoV activity in vitro, suggesting that it may be potentially beneficial the treatment of COVID-19 infections . Previous studies suggested that CQ and HCQ may inhibit the coronavirus through a series of steps: (i) by changing the pH at the surface of the cell membrane and thus, inhibiting the fusion of the virus to the cell membrane, and (ii) by inhibiting nucleic acid replication, glycosylation of viral proteins, virus assembly, new virus particle transport, virus release and other processes to achieve its antiviral effects . However, in the context of HIV,
it has been postulated that the anti-HIV- effect of these
medications results not from a direct effect on the infected
cell but rather by the inhibition of extracellular Tat effects
. Tat proteins not only promote the HIV immune
dysregulation but also participates in the HIV-associated
cardiovascular complications; hence whether CQ and HCQ
would have cardioprotective effects in the context of HIV
would be a consideration . However in June 2020,
the US Food and Drug Administration (FDA) revoked its
emergency use authorization for these agents in patients
with severe COVID-19 because data from randomized
clinical trials suggest they provided no additional clinical
benefit compared with placebo . It is of relevance that
other studies have shown some cardiotoxicities of CQ and
HCQ resulting in QTc prolongation, other arrhythmias
[53-56] and cardiomyopathies through direct lysosomal
dysfunction via inhibition of lysosomal enzymes which
could also be potentiated in the context of HIV [57,58].
Therefore, as of now the cardiovascular risks of CQ and HCQ
appear to outweigh their benefits. Yet, further research is
still necessary to clarify the role of these medications in
HIV-Tat protein-cardiovascular disease pathway and its
potential therapeutic benefits in the context of HIV.
COVID-19 Co-infections in PLHIV
At the present time, there is limited data on the risk and severity of COVID-19 infection among PLHIV. However, the European AIDS Clinical Society reported that COVID-19 infection rates were similar in PLHIV compared to HIVseronegative persons based on early reports [59-61]. As the number of cases of COVID-19 rise worldwide, these reports are clearly preliminary. Many challenges exist in estimating the prevalence of COVID-19 in PLHIV in the absence of global universal HIV testing and the absence of COVID?19 testing in patients not requiring hospitalization. This issue may also be complicated by the probable elevation of selfisolation in PLHIV due to heightened health concerns that their immune-compromised condition would render them more susceptible to more severe COVID disease course .
PLHIV have impaired immune responses even when on effective ART, and decreased responses to viral infections and vaccinations (as previously demonstrated with hepatitis B and influenza vaccines) [63-67]. The impaired immune responses may lead to higher risk and worse outcomes with any viral infection [68,69]. A small case series of PLHIV coinfected with COVID-19 in Turkey suggested that an understanding of the extent of comorbidities in PLHIV was essential in projecting mortality risk . As case reports and small studies continue to provide insight into COVID-19 coinfections in PLHIV, recent reports from the United States and Uganda have highlighted atypical presentations of weakness, fatigue, diarrhea in the absence of cough or shortness of breath [71,72]. In Spain, a study
of 47 PLHIV infected with COVID-19, found no difference
in severity of disease or death . Another case series
in Germany with 33 coinfected patients found similar
findings, with no increase in morbidity or mortality .
However, these findings should be viewed with caution
because there was no direct comparison with HIV negative
A cohort of 18 coinfected PLHIV from the United Kingdom, had significantly increased morbidity and mortality (27.8%) compared to HIV-negative counterparts . Of note, PLHIV with COVID-19 requiring hospitalization were more likely to have significantly lower median CD4 count than those hospitalized without COVID-19. It has been posited that lymphopenia in the absence of T-cell activation may blunt the severe immunologic response seen in COVID-19 . Furthermore, the incidence and severity in Spain of COVID-19 in 77,590 PLHIV receiving ART found that 236 patients were infected with COVID-19. Of these, 151 patients were hospitalized, 15 were admitted to the intensive care unit, and 20 subsequently died. These investigators reported that the risk for COVID?19 and related hospitalization was lower in PLHIV who were receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC). The authors hypothesized that nucleotide reverse transcriptase inhibitors (NRTI), such as TDF, might be effective against SARS-CoV-2 infection by inhibiting RNA-dependent RNA polymerase (RNAdRNAp) . Overall, the role of preserved relative to compromised cellular immunity on the severity of COVID-19 disease course in PLHIV is very preliminary and requires further extensive evaluation to assess the role of ART in this context.
In the midst of COVID-19 pandemic, and the potential risk to affect populations at risk, it is imperative to understand the extent to which COVID-19 may affect the health of PLHIV. Because PLHIV are now living longer and suffering of multiple comorbidities, there may be an increased risk of cardiovascular events in the setting of COVID-19. HIV infection and COVID-19 may independently lead to cardiovascular complications, but whether the coinfection provides an additive or interactive impact on cardiovascular complications is not known but is urgently needed.
Conflict of Interest
The authors confirm no relationship with industry, disclosures, or source of funding for the work presented in this manuscript.
- Director-General’s remarks at the media briefing
on 2019-nCoV on 11 February 2020.: World Health
Organization. 2020; [Available from: https://www.
- WHO. Naming the coronavirus disease (COVID-19)
and the virus that causes it World Health Organization
website. 2020; [Available from: https://www.who.int/
- University JH. COVID-19 Dashboard by the Center
for Systems Science and Engineering (CSSE) at Johns
Hopkins University (JHU) Johns Hopkins University
website. 2020; [Available from: https://gisanddata.
- Grasselli G, Pesenti A, Cecconi M. Critical care
utilization for the COVID-19 outbreak in Lombardy,
Italy: early experience and forecast during an emergency
response. Jama. 2020 Apr 28;323(16):1545-6.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and
characteristics of patients dying in relation to COVID-19 in
Italy. Jama. 2020 May 12;323(18):1775-6.
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker
C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker
PG, Fu H, Dighe A. Estimates of the severity of coronavirus
disease 2019: a model-based analysis. The Lancet
infectious diseases. 2020 Mar 30.
- Wu Z, McGoogan JM. Characteristics of and important
lessons from the coronavirus disease 2019 (COVID-19)
outbreak in China: summary of a report of 72 314 cases from
the Chinese Center for Disease Control and Prevention.
Jama. 2020 Apr 7;323(13):1239-42.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical
course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort
study. Lancet. 2020;395(10229):1054-62.
- Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM,
Masoumi A, et al. COVID-19 and Cardiovascular Disease.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I,
Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T,
Gerotziafas G, Dimopoulos MA. Hematological findings
and complications of COVID-19. American journal of
hematology. 2020 Apr 13.
- Panigada M, Bottino N, Tagliabue P, Grasselli G,
Novembrino C, Chantarangkul V, Pesenti A, Peyvandi
F, Tripodi A. Hypercoagulability of COVID-19 patients
in intensive care unit. A report of thromboelastography
findings and other parameters of hemostasis. Journal of
Thrombosis and Haemostasis. 2020 Apr 17.
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger
N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry
Depends on ACE2 and TMPRSS2 and Is Blocked by a
Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-
- Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020 Jan 1.
- MC. TCaT. Angiotensin-Converting Enzyme 2 (ACE2)
Is a Key Modulator of the Renin Angiotensin System
in Health and Disease. Int J Pept. 2012;2012:256294-
- Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis
K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular
system: implications for risk assessment, diagnosis, and
treatment options. Cardiovascular research. 2020 Apr 30.
- Puelles VG, Lütgehetmann M, Lindenmeyer MT,
Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and
Renal Tropism of SARS-CoV-2. N Engl J Med. 2020.
- Wichmann D, Sperhake JP, Lütgehetmann M, Steurer
S, Edler C, Heinemann A, et al. Autopsy Findings and
Venous Thromboembolism in Patients With COVID-19.
Ann Intern Med. 2020.
- Prevention. CfDCa. HIV Surveillance Report, 2018
(Updated), Volume 31 Published May 2020 [Available
- Centers for Disease Control and Prevention. Estimated
HIV incidence and prevalence in the United States, 2010–
2016. HIV Surveillance Supplemental Report 2019;24
(No.1). Published February 2019. [Available from: http://
- CDC. HIV Surveillance Reports: Volume 24, Number
1. 2016. Accessed from: https://www.cdc.gov/hiv/library/
- WHO. Global Health Observatory (GHO) data: World
Health Organization; 2018. Available from: who.int/gho/
- Sterne JA, Hernan MA, Ledergerber B, Tilling K,
Weber R, Sendi P, et al. Long-term effectiveness of potent
antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378-
- Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS,
Gilbert C, Oursler KK, et al. Comparison of risk and age
at diagnosis of myocardial infarction, end-stage renal
disease, and non-AIDS-defining cancer in HIV-infected
versus uninfected adults. Clinical Infectious Diseases.
- Rasmussen LD, May MT, Kronborg G, Larsen CS,
Pedersen C, Gerstoft J, et al. Time trends for risk of severe
age-related diseases in individuals with and without HIV
infection in Denmark: a nationwide population-based
cohort study. The lancet HIV. 2015;2(7):e288-e98.
- Schouten J, Wit FW, Stolte IG, Kootstra NA, van der
Valk M, Geerlings SE, et al. Cross-sectional comparison
of the prevalence of age-associated comorbidities and
their risk factors between HIV-infected and uninfected
individuals: the AGEhIV cohort study. Clinical Infectious
- Vachiat A, McCutcheon K, Tsabedze N, Zachariah
D, Manga P. HIV and Ischemic Heart Disease. J Am Coll
- Remick J, Georgiopoulou V, Marti C, Ofotokun
I, Kalogeropoulos A, Lewis W, et al. Heart failure in
patients with human immunodeficiency virus infection:
epidemiology, pathophysiology, treatment, and future
research. Circulation. 2014;129(17):1781-9.
- Shah MR. The Broad Spectrum of HIV-Related
Cardiovascular Disease. JACC Heart Fail. 2015;3(8):600-
- Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS,
Currier JS, Freiberg MS, et al. Characteristics, prevention,
and management of cardiovascular disease in people living
with HIV: a scientific statement from the American Heart
Association. Circulation. 2019;140(2):e98-e124.
- Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et
al. Association of Cardiac Injury With Mortality in
Hospitalized Patients With COVID-19 in Wuhan, China.
JAMA Cardiol. 2020.
- Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin
I in patients with coronavirus disease 2019 (COVID-19):
Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020.
- James L. Januzzi Jr. M, FACC. Troponin and BNP
Use in COVID-19. ACCorg. 2020 March 18th.
- Lakkireddy DR, Chung MK, Gopinathannair R, Patton
KK, Gluckman TJ, Turagam M, et al. Guidance for Cardiac
Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task
Force; Electrophysiology Section of the American College of
Cardiology; and the Electrocardiography and Arrhythmias
Committee of the Council on Clinical Cardiology, American
Heart Association. Circulation. 2020.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.
Clinical Characteristics of 138 Hospitalized Patients With
2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
China. Jama. 2020;323(11):1061-9.
- Prutkin JM. Coronavirus disease 2019 (COVID-19):
Arrhythmias and conduction system disease 2020
Available from: https://www.uptodate.com/contents/
- Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al.
Prevalence and impact of cardiovascular metabolic diseases
on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-
- Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue
PY, Fuster V, et al. Inflammation, Immunity, and Infection
in Atherothrombosis: JACC Review Topic of the Week. J
Am Coll Cardiol. 2018;72(17):2071-81.
- Chapman AR, Bularga A, Mills NL. High-Sensitivity
Cardiac Troponin Can Be An Ally in the Fight Against
COVID-19. Circulation. 2020.
- Roffi M, Guagliumi G, Ibanez B. The Obstacle Course
of Reperfusion for STEMI in the COVID-19 Pandemics.
- Varga Z, Flammer AJ, Steiger P, Haberecker
M, Andermatt R, Zinkernagel AS, et al. Endothelial
cell infection and endotheliitis in COVID-19. Lancet.
- Caforio AL, Pankuweit S, Arbustini E, Basso C,
Gimeno-Blanes J, Felix SB, et al. Current state of knowledge
on aetiology, diagnosis, management, and therapy
of myocarditis: a position statement of the European
Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48,
- Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M,
Tomasoni D, et al. Cardiac Involvement in a Patient With
Coronavirus Disease 2019 (COVID-19). JAMA Cardiol.
- Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX,
et al. First case of COVID-19 complicated with fulminant
myocarditis: a case report and insights. Infection. 2020:1-
- Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant
myocarditis saved with glucocorticoid and human
immunoglobulin. Eur Heart J. 2020.
- Kim IC, Kim JY, Kim HA, Han S. COVID-19-related
myocarditis in a 21-year-old female patient. Eur Heart J.
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al.
Pathological findings of COVID-19 associated with acute
respiratory distress syndrome. The Lancet Respiratory
- Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy
Brown J, Vander Heide RS. Pulmonary and cardiac
pathology in African American patients with COVID-19: an
autopsy series from New Orleans. The Lancet Respiratory
- Biot C, Daher W, Chavain N, Fandeur T, Khalife J,
Dive D, et al. Design and synthesis of hydroxyferroquine
derivatives with antimalarial and antiviral activities. J
Med Chem. 2006;49(9):2845-9.
- Fox RI. Mechanism of action of hydroxychloroquine as
an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2
- Rayne F, Vendeville A, Bonhoure A, Beaumelle B. The
Ability of Chloroquine To Prevent Tat-Induced Cytokine
Secretion by Monocytes Is Implicated in Its In Vivo Anti-
Human Immunodeficiency Virus Type 1 Activity. Journal
of Virology. 2004;78(21):12054-7.
- Jiang Y, Chai L, Fasae MB, Bai Y. The role of HIV Tat
protein in HIV-related cardiovascular diseases. Journal of
Translational Medicine. 2018;16(1):121.
- FDA U. Coronavirus (COVID-19) Update: FDA
Revokes Emergency Use Authorization for Chloroquine
and Hydroxychloroquine. June 15, 2020. Available
- Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et
al. Hydroxychloroquine in patients with mainly mild
to moderate coronavirus disease 2019: open label,
randomised controlled trial. Bmj. 2020;369:m1849.
- Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP,
Veiga VC, Avezum A, et al. Hydroxychloroquine with or
without Azithromycin in Mild-to-Moderate Covid-19. N
Engl J Med. 2020.
- Mahévas M, Tran VT, Roumier M, Chabrol A, Paule
R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine
in patients with covid-19 pneumonia who require oxygen observational comparative study using routine care data.
- Borba MGS, Val FFA, Sampaio VS, Alexandre MAA,
Melo GC, Brito M, et al. Effect of High vs Low Doses of
Chloroquine Diphosphate as Adjunctive Therapy for
Patients Hospitalized With Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) Infection:
A Randomized Clinical Trial. JAMA Netw Open.
- Yogasundaram H, Hung W, Paterson ID, Sergi C, Oudit
GY. Chloroquine-induced cardiomyopathy: a reversible
cause of heart failure. ESC Heart Fail. 2018;5(3):372-5.
- Yogasundaram H, Putko BN, Tien J, Paterson DI,
Cujec B, Ringrose J, et al. Hydroxychloroquine-induced
cardiomyopathy: case report, pathophysiology, diagnosis,
and treatment. Can J Cardiol. 2014;30(12):1706-15.
- Blanco JL, Ambrosioni J, Garcia F, Martinez E,
Soriano A, Mallolas J, et al. COVID-19 in patients with
HIV: clinical case series. Lancet HIV. 2020;7(5):e314-e6.
- Harter G, Spinner CD, Roider J, Bickel M, Krznaric I,
Grunwald S, et al. COVID-19 in people living with human
immunodeficiency virus: a case series of 33 patients.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM,
McGinn T, Davidson KW, et al. Presenting Characteristics,
Comorbidities, and Outcomes Among 5700 Patients
Hospitalized With COVID-19 in the New York City Area.
- Jones R, Nelson M, Bracchi M, Asboe D, Boffito M.
COVID-19 in patients with HIV. Lancet HIV. 2020.
- Kroon FP, van Dissel JT, de Jong JC, Zwinderman K,
van Furth R. Antibody response after influenza vaccination
in HIV-infected individuals: a consecutive 3-year study.
- Meyaard L, Otto SA, Hooibrink B, Miedema F.
Quantitative analysis of CD4+ T cell function in the course
of human immunodeficiency virus infection. Gradual
decline of both naive and memory alloreactive T cells. The
Journal of clinical investigation. 1994;94(5):1947-52.
- Pasricha N, Datta U, Chawla Y, Singh S, Arora SK, Sud
A, et al. Immune responses in patients with HIV infection
after vaccination with recombinant Hepatitis B virus
vaccine. BMC infectious diseases. 2006;6(1):65.
- Pallikkuth S, De Armas LR, Pahwa R, Rinaldi S,
George VK, Sanchez CM, et al. Impact of aging and HIV
infection on serologic response to seasonal influenza
vaccination. Aids. 2018;32(9):1085-94.
- George VK, Pallikkuth S, Parmigiani A, Alcaide M,
Fischl M, Arheart KL, et al. HIV infection Worsens Age-
Associated Defects in Antibody Responses to Influenza
Vaccine. J Infect Dis. 2015;211(12):1959-68.
- Maartens G, Griesel R, Dube F, Nicol M, Mendelson
M. Etiology of Pulmonary Infections in Human
Immunodeficiency Virus-infected Inpatients Using
Sputum Multiplex Real-time Polymerase Chain Reaction.
Clin Infect Dis. 2020;70(6):1147-52.
- Lerner AM, Eisinger RW, Fauci AS. Comorbidities
in Persons With HIV: The Lingering Challenge. JAMA.
- Altuntas Aydin O, Kumbasar Karaosmanoglu H,
Kart Yasar K. HIV/SARS-CoV-2 co-infected patients in
Istanbul, Turkey. Journal of Medical Virology. 2020.
- Baluku JB, Mwebaza S, Ingabire G, Nsereko C,
Muwanga M. HIV and SARS-CoV-2 co-infection: A case
report from Uganda. J Med Virol. 2020.
- Patel RH, Pella PM. COVID-19 in a patient with HIV
infection. J Med Virol. 2020.
- Gervasoni C, Meraviglia P, Riva A, Giacomelli A,
Oreni L, Minisci D, et al. Clinical features and outcomes
of HIV patients with coronavirus disease 2019. Clin Infect
- Härter G, Spinner CD, Roider J, Bickel M, Krznaric I,
Grunwald S, et al. COVID-19 in people living with human
immunodeficiency virus: a case series of 33 patients.
- Fujita T, Yamasaki T, Kamio Y, Hirose S, Tobimatsu
S. Parvocellular pathway impairment in autism spectrum
disorder: Evidence from visual evoked potentials. Research
in Autism Spectrum Disorders. 2011 Jan 1;5(1):277-85.
- Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E,
Quinn K, et al. Hospitalized Patients With COVID-19 and
Human Immunodeficiency Virus: A Case Series. Clinical
Infectious Diseases. 2020.
- Mascolo S, Romanelli A, Carleo MA, Esposito V.
Could HIV infection alter the clinical course of SARSCoV-
2 infection? When less is better. Journal of Medical
- Del Amo J, Polo R, Moreno S, Diaz A, Martinez E,
Arribas JR, et al. Incidence and Severity of COVID-19 in
HIV-Positive Persons Receiving Antiretroviral Therapy: A
Cohort Study. Ann Intern Med. 2020.